Nukleozydo i oligonukleozydo boranofosfoniany : metody syntezy i wybrane właściwości biologiczne

• Autorzy: Gołębiewska Justyna

Warianty tytułu

EN

Nucleoside and oligonucleoside boranephosphonates : synthetic methods and selected biological properties

• Języki publikacji: PL

Abstrakty

EN

Interest in boron-containing compounds has grown in recent years due to their potential medicinal and biochemical applications. Nucleoside boranephosphonates are analogues of naturally occurring nucleoside phosphates in which one of the non- bridging oxygen atom has been replaced by a BH₃ group [1]. This modification imparts unique biological properties to nucleotides and nucleic acids. DNA and RNA fragments containing boranephosphonate internucleotide linkages are resistant to various nucleases, stimulate the RNase H activity, and reveal high lipophilicity, which significantly enhances their cellular uptake [2]. The hydrolytic stability and nuclease resistance make these compounds attractive candidates in designing new therapeutics and medicinal diagnostics. Considering these characteristics nucleoside boranephosphonates constitute a promising class of nucleotide analogues worth exploring for biological purposes.

Słowa kluczowe

PL

nukleozydo boranofosfoniany; strategie syntetyczne; odporność na nukleazy; aktywność biologiczna

EN

nucleoside boranephosphonate; synthetic strategies; nuclease resistance; biological activity

• Wydawca: Polskie Towarzystwo Chemiczne
• Czasopismo: Wiadomości Chemiczne
• Rocznik: 2020
• Tom: [Z] 74, 7-8
• Strony: 477--506
• Opis fizyczny: Bibliogr. 63 poz., schem.

Twórcy

autor

Gołębiewska Justyna

• Instytut Chemii Bioorganicznej Polskiej Akademii Nauk, ul. Z. Noskowskiego 12/14, 61-704 Poznań

Bibliografia

• [1] J.S. Summers, B.R. Shaw, Curr. Med. Chem., 2001, 8, 1147.
• [2] B.R. Shaw, M. Dobrikov, X.I.N. Wang, J. Wan, K. He, J.-L. Lin, P. Li, V. Rait, Z.A. Sergueeva, D. Sergueev, Ann. N.Y. Acad. Sci., 2003, 1002, 12.
• [3] Y. Endo, T. Yoshimi, C. Miyaura, Pure Appl. Chem., 2003, 75, 1197.
• [4] W. Yang, X. Gao, B. Wang, Med. Res. Rev., 2003, 23, 346.
• [5] A. Adamczyk-Woźniak, К. Czerwińska, I.D. Madura, A. Matuszewska, A. Sporzyński, A. Żubrowska-Zembrzuska, New J. Chem., 2015, 39, 4308.
• [6] R.F. Barth, Z. Zhang, T. Liu, Cancer Commun., 2018, 38, 36.
• [7] S.C. Quah, J. Xiangya Med., 2018, 3, 29.
• [8] T.H. Hall, B.S. Burnham, K.G. Rajendran, S.Y. Chen, A. Sood, B.F. Spielvoge, B.R. Shaw, Biomed. Pharmacother., 1993, 47, 79.
• [9] A. Sood, B.R. Shaw, B.F. Spielvogel, J. Am. Chem. Soc., 1990, 112, 9000.
• [10] L. Wang, S. Jiang, Z. Deng, P.C. Dedon, S. Chen, Microbiol. Rev., 2019, 43, 109.
• [11] P.S. Miller, Non-ionic antisense oligonucleotides, in: J.S. Cohen (Ed.) Oligonucleotides-Antisense Inhibitors of Gene Expression, The Macmillan Press Itd, New York, 1989.
• [12] P. Li, B.R. Shaw, Chem. Commun., 2002, 2890.
• [13] K.W. Porter, J.D. Briley, B.R. Shaw, Nucleic Acids Res., 1997, 25, 1611.
• [14] A.H. Hall, J. Wan, E.E. Shaughnessy, B. Ramsay Shaw, K.A. Alexander, Nucleic Acids Res., 2004, 32, 5991.
• [15] A.H. Hall, J. Wan, A. Spesock, Z. Sergueeva, B.R. Shaw, K.A. Alexander, Nucleic Acids Res., 2006, 34, 2773.
• [16] B. Schneider, P. Meyer, S. Sarfati, L. Mulard, C. Guerreiro, J. Boretto, J. Janin, M. Veron, D. Deville-Bonne, B. Canard, Nucleos. Nucleot. Nucl. Acids, 2001, 20, 297.
• [17] P. Meyer, B. Schneider, S. Safati, D. Deville-Bonne, C. Guerreiro, J. Boretto, J. Janin, M. Veron, B. Canard, EMBO J., 2000, 19, 3520.
• [18] P. Li, Z.A. Sergueeva, M. Dobrikov, B.R. Shaw, Chem. Rev., 2007, 107, 4746.
• [19] J. Tomasz, B.R. Shaw, K. Porter, B.F. Spielvogel, A. Sood, Angew. Chem., Int. Ed. Engl., 1992, 31, 1373.
• [20] S.I. Khan, M.I. Dobrikov, B.R. Shaw, Nucleos. Nucleot. Nucl. Acids, 2005, 24, 1047.
• [21] J. Stawinski, A. Kraszewski, Acc. Chem. Res., 2002, 35, 952.
• [22] J. Nilsson, M. Bollmark, J. Jankowska, M. Wenska, J. Cieslak, A. Kraszewski, J. Stawinski, Phosphorus, Sulfur, and Silicon, 2002, 177, 1513.
• [23] P.J. Garegg, T. Regberg, J. Stawiński, R. Strömberg, J. Chem. Soc. Perkin Trans. I, 1987, 1269.
• [24] M.A. Maier, A.P. Guzaev, M. Manoharan, Org. Lett., 2000, 2, 1819.
• [25] J. Stawinski, M. Thelin, J. Org. Chem., 1991.
• [26] T. Szabo, A. Kers, J. Stawinski, Nucleic Acids Res., 1995, 23, 893.
• [27] J. Zhang, T. Terhorst, M.D. Matteucci, Tetrahedron Lett., 1997, 38, 4957.
• [28] T. Imamoto, E. Nagato, Y. Wada, H. Masuda, K. Yamaguchi, T. Uchimaru, J. Am. Chem. Soc., 1997, 119, 9925.
• [29] K. Vyakaranam, G. Rana, B.F. Spielvogel, J.A. Maguire, N.S. Hosmane, Nucleos. Nucleot. Nucl. Acids, 2002, 21, 581.
• [30] Y. Nukaga, T. Wada, Chemical Synthesis of Boranophosphate Deoxy-ribonucleotides, in: Synthesis of Therapeutic Oligonucleotides, 2018.
• [31] Z.A. Sergueeva, D.S. Sergueev, B.R. Shaw, Nucleos. Nucleot. Nucl. Acids, 2001, 20, 941.
• [32] H.B. McCuen, M.S. Noe, A.B. Sierzchala, A.P. Higson, M.H. Caruthers, J. Am. Chem. Soc., 2006, 128, 8138.
• [33] D.S. Sergueev, B.R. Shaw, J. Am. Chem. Soc., 1998, 120, 9417.
• [34] A.P. Higson, A.B. Sierzchala, H. Brummel, Z. Zhao, M.H. Caruthers, Tetrahedron Lett., 1998, 39, 3899.
• [35] T. Wada, Y. Sato, F. Honda, S. Kawahara, M. Sekine, J. Am. Chem. Soc., 1997, 119, 12710.
• [36] D.S. Sergueev, Z.A. Sergueeva, B.R. Shaw, Nucleos. Nucleot. Nucl. Acids, 2001, 20, 789.
• [37] T. Kawanaka, M. Shimizu, N. Shintani, T. Wada, Bioorg. Med. Chem. Lett., 2008, 18, 3783.
• [38] M. Shimizu, K. Saigo, T. Wada, J. Org. Chem., 2006, 71, 4262.
• [39] R. Higashida, N. Oka, T. Kawanaka, T. Wada, Chem. Commun., 2009, 2466.
• [40] S. Uehara, S. Hiura, R. Higashida, N. Oka, T. Wada, J. Org. Chem., 2014, 79, 3465.
• [41] T. Wada, Y. Maizuru, M. Shimizu, N. Oka, K. Saigo, Bioorg. Med. Chem. Lett., 2006, 16, 3111.
• [42] N. Iwamoto, N. Oka, T. Sato, T. Wada, Angew. Chem. Int. Ed. Engl., 2009, 48, 496.
• [43] N. Iwamoto, N. Oka, T. Wada, Tetrahedron Lett., 2012, 53, 4361.
• [44] R.I. Hara, T. Saito, T. Kogure, Y. Hamamura, N. Uchiyama, Y. Nukaga, N. Iwamoto, T. Wada, J. Org. Chem., 2019, 84, 7971.
• [45] H. Li, K. Porter, F. Huang, B.R. Shaw, Nucleic Acids Res., 1995, 23, 4495.
• [46] E. De Clercq, Nat. Rev. Drug Discov., 2002, 1, 13.
• [47] J. Romanowska, M. Sobkowski, A. Szymanska-Michalak, K. Kolodziej, A. Dabrowska, A. Lipniacki, A. Piasek, Z.M. Pietrusiewicz, M. Figlerowicz, A. Guranowski, J. Boryski, J. Stawinski, A. Kraszewski, J. Med. Chem., 2011, 54, 6482.
• [48] G.W.G. Shu-ling Chang, Peter J. Southern, Carston R. Wagner, J. Med. Chem., 2001, 44, 223.
• [49] P. Li, B.R. Shaw, Nucleos. Nucleot. Nucl. Acids, 2005, 24, 675.
• [50] P. Li, B.R. Shaw, J. Org. Chem., 2005, 70, 2171.
• [51] B. Selmi, J. Boretto, S.R. Sarfati, C. Guerreiro, B. Canard, J. Biol. Chem., 2001, 276, 48466.
• [52] J. Deval, B. Selmi, J. Boretto, M.P. Egloff, C. Guerreiro, S. Sarfati, B. Canard, J. Biol. Chem., 2002, 277, 42097.
• [53] G. Meister, T. Tuschl, Nature, 2004, 431, 343.
• [54] A.H.S. Hall, J. Wan, A. Spesock, Z. Sergueeva, B.R. Shaw, K.A. Alexander, Nucleic Acids Res., 2006, 34, 2773.
• [55] Y. Chiu, T.M. Rana, Mol. Cell, 2002, 10, 549.
• [56] A.M. Rossor, M.M. Reilly, J.N. Sleigh, Pract. Neurol., 2018, 18, 126.
• [57] F.-C.Q. Yao-Quan Chen, Yi-Bing Zhang, Tetrahedron Lett., 1995, 36, 745.
• [58] B. Krzyzanowska, H. Kaizhang, A. Hasan, S. B.R, Tetrahedron 1998, 54, 5119.
• [59] K. He, A. Hasan, B. Krzyzanowska, B.R. Shaw, J. Org. Chem., 1998, 63, 5769.
• [60] J. Wan, B.R. Shaw, Nucleos. Nucleot. Nucl. Acids, 2005, 24, 943.
• [61] J. Golebiewska, J. Stawinski, J. Org. Chem., 2020, 85, 4312.
• [62] S. Paul, S. Roy, L. Monfregola, S. Shang, R. Shoemaker, M.H. Caruthers, J. Am. Chem. Soc., 2015, 137, 3253.
• [63] J. Golebiewska, M. Rachwalak, T. Jakubowski, J. Romanowska, J. Stawinski, J. Org. Chem., 2018, 83

Uwagi

Opracowanie rekordu ze środków MNiSW, umowa Nr 461252 w ramach programu "Społeczna odpowiedzialność nauki" - moduł: Popularyzacja nauki i promocja sportu (2020).